XML 63 R45.htm IDEA: XBRL DOCUMENT
v3.25.1

SEGMENTS AND CONCENTRATIONS (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
SCHEDULE OF SEGMENT NET REVENUES | Segment net revenues, segment operating expenses and segment contribution information consisted of the following: SCHEDULE OF SEGMENT NET REVENUES
|  | Branded |  |  | ImprimisRx |  |  | Consolidated |
|  | Year Ended December 31, 2024 |
|  | Branded |  |  | ImprimisRx |  |  | Consolidated |
Product sales, net |  | $ | 115,120,000 |  |  | $ | 83,499,000 |  |  | $ | 198,619,000 |
Other revenues |  |  | 995,000 |  |  |  | - |  |  |  | 995,000 |
Total revenues |  |  | 116,115,000 |  |  |  | 83,499,000 |  |  |  | 199,614,000 |
Cost of sales |  |  | (21,667,000 | ) |  |  | (27,578,000 | ) |  |  | (49,245,000 | )
Gross profit |  |  | 94,448,000 |  |  |  | 55,921,000 |  |  |  | 150,369,000 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  | 62,301,000 |  |  |  | 23,607,000 |  |  |  | 85,908,000 |
Research and development |  |  | 2,890,000 |  |  |  | 386,000 |  |  |  | 3,276,000 |
Segment contribution |  | $ | 29,257,000 |  |  | $ | 31,928,000 |  |  |  | 61,185,000 |
Corporate |  |  |  |  |  |  |  |  |  |  | 43,409,000 |
Research and development |  |  |  |  |  |  |  |  |  |  | 8,954,000 |
Income from operations |  |  |  |  |  |  |  |  |  | $ | 8,822,000 |
|  | Branded |  |  | ImprimisRx |  |  | Consolidated |
|  | Year Ended December 31, 2023 |
|  | Branded |  |  | ImprimisRx |  |  | Consolidated |
Product sales, net |  | $ | 37,512,000 |  |  | $ | 79,935,000 |  |  | $ | 117,447,000 |
Other revenues |  |  | 12,746,000 |  |  |  | - |  |  |  | 12,746,000 |
Total revenues |  |  | 50,258,000 |  |  |  | 79,935,000 |  |  |  | 130,193,000 |
Cost of sales |  |  | (12,662,000 | ) |  |  | (26,978,000 | ) |  |  | (39,640,000 | )
Gross profit |  |  | 37,596,000 |  |  |  | 52,957,000 |  |  |  | 90,553,000 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Selling, general and administrative |  |  | 18,126,000 |  |  |  | 29,210,000 |  |  |  | 47,336,000 |
Research and development |  |  | 641,000 |  |  |  | 966,000 |  |  |  | 1,607,000 |
Segment contribution |  | $ | 18,829,000 |  |  | $ | 22,781,000 |  |  |  | 41,610,000 |
Corporate |  |  |  |  |  |  |  |  |  |  | 36,134,000 |
Research and development |  |  |  |  |  |  |  |  |  |  | 5,045,000 |
Income from operations |  |  |  |  |  |  |  |  |  | $ | 431,000 |
SCHEDULE OF REVENUES BY SEGMENT | Revenues by segment are further described as follows: SCHEDULE OF REVENUES BY SEGMENT
|  | For the Years Ended |
|  | December 31, |
|  | 2024 |  |  | % |  |  | 2023 |  |  | % |
IHEEZO |  | $ | 49,303,000 |  |  |  | 25 | % |  | $ | 20,621,000 |  |  |  | 16 | %
VEVYE |  |  | 28,061,000 |  |  |  | 14 | % |  |  | 1,766,000 |  |  |  | 1 | %
Other branded products |  |  | 37,836,000 |  |  |  | 19 | % |  |  | 15,125,000 |  |  |  | 12 | %
Other revenue, net |  |  | 915,000 |  |  |  | 0 | % |  |  | 12,746,000 |  |  |  | 10 | %
Branded revenue, net |  |  | 116,115,000 |  |  |  | 58 | % |  |  | 50,258,000 |  |  |  | 39 | %
ImprimisRx revenue, net |  |  | 83,499,000 |  |  |  | 42 | % |  |  | 79,935,000 |  |  |  | 61 | %
Total revenues, net |  | $ | 199,614,000 |  |  |  | 100 | % |  | $ | 130,193,000 |  |  |  | 100 | %

X
- Definition Schedule Of Segment Reporting Information [Text Block] + References No definition available. + Details
Name: | HROW_ScheduleOfSegmentReportingInformationTextBlock
Namespace Prefix: | HROW_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration